Israel - heprea - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - טבליות מצופות פילם - venetoclax 100 mg - venetoclax

Israel - heprea - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - טבליות מצופות פילם - venetoclax 50 mg - venetoclax

Israel - heprea - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - טבליות מצופות פילם - venetoclax 50 mg - venetoclax

Israel - heprea - Ministry of Health

gilead sciences israel ltd - ledipasvir; sofosbuvir - טבליות מצופות פילם - ledipasvir 90 mg; sofosbuvir 400 mg - sofosbuvir and ledipasvir

Israel - heprea - Ministry of Health

gilead sciences israel ltd - ledipasvir; sofosbuvir - טבליות מצופות פילם - ledipasvir 90 mg; sofosbuvir 400 mg - sofosbuvir and ledipasvir

Israel - heprea - Ministry of Health

gilead sciences israel ltd - ledipasvir; sofosbuvir - טבליות מצופות פילם - ledipasvir 90 mg; sofosbuvir 400 mg - sofosbuvir and ledipasvir

Israel - heprea - Ministry of Health

sanofi israel ltd - thyrotropin alfa - אבקה להכנת תמיסה לזריקה - thyrotropin alfa 0.9 mg/ml - thyrotropin - thyrotropin - adjunctive diagnostic tool for serum thyroglobulin (tg) testing with or without radioiodine imaging in the followup of patients with well-differentiated thyroid cancer.adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer.

Israel - heprea - Ministry of Health

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.

Israel - heprea - Ministry of Health

novartis israel ltd - secukinumab - תמיסה להזרקה - secukinumab 150 mg/ml - secukinumab

Israel - heprea - Ministry of Health

novartis israel ltd - canakinumab - תמיסה להזרקה - canakinumab 150 mg / 1 ml - canakinumab